Cellusion
Manufacturing induced pluripotent stem cell-derived corneal endothelial cells for bullous keratopathy therapy.
Launch date
Employees
Market cap
-
Enterprise valuation
€79—119m (Dealroom.co estimates Jun 2023.)
Tokyo Japan (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | JPY8.0m | Early VC | |
| N/A | JPY20.0m | Seed | |
| N/A | JPY20.0m | Seed | |
| N/A | JPY50.0m | Seed | |
N/A | Grant | ||
$3.3m | Series A | ||
| N/A | $1.0m | Early VC | |
JPY1.1b | Late VC | ||
* | JPY2.8b | Series C | |
| Total Funding | €32.1m | ||